Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
Description
Cephalosporin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global cephalosporin market size reached US$ 18.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 2.83% during 2023-2028.
Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.
At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cephalosporin market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on generation, route of administration and application.
Breakup by Generation:
First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation
Breakup by Route of Administration:
Injection
Oral
Breakup by Application:
Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection
Others
Breakup by Region:
Asia Pacific
Europe
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.
Key Questions Answered in This Report
1. What was the size of the global cephalosporin market in 2022?
2. What is the expected growth rate of the global cephalosporin market during 2023-2028?
3. What are the key factors driving the global cephalosporin market?
4. What has been the impact of COVID-19 on the global cephalosporin market?
5. What is the breakup of the global cephalosporin market based on the generation?
6. What is the breakup of the global cephalosporin market based on the route of administration?
7. What are the key regions in the global cephalosporin market?
8. Who are the key players/companies in the global cephalosporin market?
The global cephalosporin market size reached US$ 18.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 2.83% during 2023-2028.
Cephalosporins are beta-lactam antibiotics that function in the way similar to penicillin. These broad-spectrum drugs help in treating numerous bacterial infections such as pneumonia, kidney infections, bone infections, meningitis and various sexually transmitted diseases (STDs). There are currently five generations of cephalosporin drugs available in the market with a slight difference in their antibacterial spectrum. These medicines are also differentiated on the basis their administration, excretion, absorption and the duration of the effect of cephalosporin on the body. There are two ways to administer cephalosporin drugs, namely, oral and intravenous (IV). A course of oral cephalosporins is generally used for curing minor infections that are easy to treat such as strep throat. Whereas, IVs are utilized for more severe infections, like meningitis, as these medicines reach tissues quickly than those administered orally.
At present, the rapidly increasing water and air pollution are the primary reasons for the prevalence of infectious diseases across the globe. This has provided a boost to the demand for cephalosporin drugs worldwide. Other than this, various organizations around the world are taking initiatives to improve the development and delivery of antibiotic treatments. One such program is the Global Antibiotic Research and Development Partnership (GARDP), which is a not-for-profit R&D organization formed by the Drugs for Neglected Disease initiative (DNDi) and World Health Organization (WHO). It focusses on the promotion of public-private partnerships for increasing R&D of new antimicrobial diagnostics and agents. The formation of these partnerships is expected to play a significant role in the growth of the cephalosporin market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cephalosporin market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on generation, route of administration and application.
Breakup by Generation:
First Generation
Second Generation
Third Generation
Fourth Generation
Fifth Generation
Breakup by Route of Administration:
Injection
Oral
Breakup by Application:
Respiratory Tract
Skin Infection
Ear Infection
Urinary Tract Infection
Sexually Transmitted Infection
Others
Breakup by Region:
Asia Pacific
Europe
North America
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Limited, Merck & Co. Inc., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Abbott, Sun Pharmaceutical Industries Limited, etc.
Key Questions Answered in This Report
1. What was the size of the global cephalosporin market in 2022?
2. What is the expected growth rate of the global cephalosporin market during 2023-2028?
3. What are the key factors driving the global cephalosporin market?
4. What has been the impact of COVID-19 on the global cephalosporin market?
5. What is the breakup of the global cephalosporin market based on the generation?
6. What is the breakup of the global cephalosporin market based on the route of administration?
7. What are the key regions in the global cephalosporin market?
8. Who are the key players/companies in the global cephalosporin market?
Table of Contents
110 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Cephalosporin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Generation
- 5.5 Market Breakup by Route of Administration
- 5.6 Market Breakup by Application
- 5.7 Market Breakup by Region
- 5.8 Market Forecast
- 6 Market Breakup by Generation
- 6.1 First Generation
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Second Generation
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Third Generation
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Fourth Generation
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Fifth Generation
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 7 Market Breakup by Route of Administration
- 7.1 Injection
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Oral
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 8 Market Breakup by Application
- 8.1 Respiratory Tract
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Skin Infection
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ear Infection
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Urinary Tract Infection
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Sexually Transmitted Infection
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 9 Market Breakup by Region
- 9.1 Asia Pacific
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Europe
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 North America
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Middle East and Africa
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Latin America
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
- 10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 13.1 Price Indicators
- 13.2 Price Structure
- 13.3 Margin Analysis
- 14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Allergan Plc.
- 14.3.2 Bristol-Myers Squibb Company
- 14.3.3 F. Hoffmann-La Roche Ltd.
- 14.3.4 GlaxoSmithKline plc
- 14.3.5 Lupin Limited
- 14.3.6 Merck & Co. Inc.
- 14.3.7 Novartis International AG (Sandoz)
- 14.3.8 Pfizer Inc.
- 14.3.9 Sanofi
- 14.3.10 Teva Pharmaceutical Industries Ltd.
- 14.3.11 Abbott
- 14.3.12 Sun Pharmaceutical Industries Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
